OTR Therapeutics
San Diego, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $100M
Overview
Developing biologic therapies targeting retinal vascular leakage and inflammation in ocular diseases.
Ophthalmology
Technology Platform
Monoclonal antibody platform targeting the Potentiation of EphB4 pathway to inhibit vascular leakage and inflammation in retinal diseases.
Funding History
1Total raised:$100M
Venture$100M
Opportunities
Potential to capture market share in the large diabetic eye disease population with a differentiated therapeutic profile.
Risk Factors
Clinical and regulatory risk in demonstrating superiority or non-inferiority against entrenched, highly effective standard-of-care biologics.
Competitive Landscape
Enters a crowded anti-VEGF market but offers a novel mechanism that could address treatment-resistant patients or be used in combination therapies.